Amgen Signs an Immuno-Oncology Agreement with Molecular Partners' for its MP0310
Shots:
- Molecular to receive $50M upfront- $497M milestone and royalties on sales and also has certain rights to commercialize DARPin based products with MP0310. Amgen to get exclusive worldwide development and commercialization rights for Molecular’s MP0310
- The companies will jointly evaluate MP0310 with Amgen’s oncology product and BiTE (bispecific T cell engager) molecules- with defined cost sharing for first three indications
- Molecular’s MP0310 is a pre-clinical- FAP x 4-1BB DARPin Molecule- targeted for activation of immune cells in tumor by binding FAP & T cells via 4-1BB (immune modulator)\
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
